Follow-The-Filings

Security · featured owners

PTGX

Protagonist Therapeutics Inc. COM Equity as of 2026 Q2 among managers we track

  • 5 Owners
  • Max 3.6%
  • $821M
  • 2 add 1 reduce

Who owns this now

Largest portfolio weights among featured holders · max 3.6% (Farallon Capital Management) · not free-float ownership

  1. Farallon Capital Management 3.6%
  2. James Silverman 1.1%
  3. Stanley Druckenmiller add 0.5%
  4. Polen Capital Management reduce 0.02%

holders

sorted by % of portfolio · long equity only · open a manager for their book

history
Farallon Capital Management 2026 Q2 3.6% Hold 6,348,906 $778M hist
James Silverman - Opaleye Management 2026 Q2 1.1% Hold 100,000 $12M hist
Stanley Druckenmiller - Duquesne Family Office 2026 Q2 0.5% Add +30.8% 208,900 $26M hist
Polen Capital Management 2026 Q2 0.02% Reduce −6.9% 22,651 $3M hist
Ron Baron - Bamco Inc. /NY/ (Baron Capital) 2026 Q2 0% Add +6.7% 16,000 $2M hist

5 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue — — —
Gross profit — — —
Gross margin — — —
Net income -$78.96M $275.19M -$130.15M
Net margin — — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $355.58M $591.64M $577.57M
Total non-current assets * $2.37M $153.08M $90.61M
Total assets $357.95M $744.72M $668.19M
Total current liabilities $21.27M $47.4M $45.44M
Total non-current liabilities * $0.00 $22.03M $8.04M
Total equity $336.68M $675.3M $614.71M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$70.24M $184.15M $57.67M
Cash from investing -$39.26M -$299.48M -$49.33M
Cash from financing $170.48M $25.85M $22.86M
Net change in cash $60.98M -$89.48M $31.2M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders